About Genexine
Genexine is a publicly listed company based in Seongnam-si (South Korea) founded in 2002 by Young Chul Sung. Immunotherapeutics for orphan diseases, cancers, and autoimmune disorders are developed. The company has 89 employees. Genexine has completed 1 acquisition, including Argos Therapeutics. Its chief executive, as recorded, is Neil Warma. Its focus areas include Life Sciences, Immunotherapy, Antibody and Disease-Targeting.
Company details
Genexine was founded in 2002 in Seongnam-si, South Korea. Focus is placed on developing immunotherapeutics targeting orphan diseases, cancers, and autoimmune disorders within the biotechnology sector. Drug candidates for growth hormone deficiencies, cervical cancers, and anemias have been advanced. The technology platform relies on Fc fusion proteins and DNA vaccines for these operations.
- Headquarters Seongnam-si, South Korea
- Employees 89
- Founders Young Chul Sung
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website genexine.com
- Social LinkedIn Facebook
- Legal Name Genexine, Inc.
- Annual Revenue$3.16 M (USD)55.96as on Dec 31, 2025
- Net Profit-$18.85 M (USD)57.28as on Dec 31, 2025
- EBITDA-$20.11 M (USD)8.59as on Dec 31, 2025
- Latest Funding Round$233M (USD), Post-IPO
Mar 2018
- Investors
- Employee Count89
- Investments & Acquisitions
Funding Insights of Genexine
- Total Rounds 2
- Last Round Post-IPO — $233M
- Investors Count 1
All 2 funding rounds of Genexine with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $233M | Post-IPO | – | – | – |
| Oct 2012 | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in Genexine
Genexine has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Handok.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| handok.co.kr |
Investor details for Genexine
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genexine
2 people are tracked at Genexine (2 in leadership); the tracked headcount is 89.
| Name | Role | Group |
|---|---|---|
Young Chul Sung | Founder & Chairman | Leadership |
Neil Warma | CEO | Leadership |
Complete people profiles for Genexine
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genexine
Genexine is a publicly listed company on the KRX with ticker symbol 095700 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Sep 2009
- Listed onKRX: 95700
- Listed entityGenexine, Inc.
- Exchange sectorHealth technology
- ISINKR7095700001
- Share price2,690.00 KRW (-1.82% on the day) · 2026-10-14
- Market capitalisation124,614,289,398.00 KRW
- EPS (diluted, trailing year)-710.21 KRW
- Volume (last session)116,714
Financials of Genexine
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 4.57B KRW | -27.22B KRW | -29.04B KRW |
| 2024 | 2.93B KRW | -63.71B KRW | -31.77B KRW |
| 2023 | 4.43B KRW | -66.87B KRW | -36.90B KRW |
| 2022 | 16.14B KRW | -55.97B KRW | -28.87B KRW |
| 2021 | 36.83B KRW | -48.04B KRW | -22.17B KRW |
Detailed financial statements for Genexine
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genexine
Genexine has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Argos Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
An online gambling platform is operated for Tai Xiu games. | argostherapeutics.com | Durham, United States | 1997 | Feb 2019 | $11.12M |
Complete acquisition details for Genexine
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Genexine
5 dated milestones of Genexine across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Genexine is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round.
- Funding Latest funding round, Post-IPO, of $233.0M.
- Acquisition Acquires Argos Therapeutics.
Web traffic of Genexine
The website of Genexine (genexine.com) receives about 2.6K visits a month and ranks #5,347,385 among all websites worldwide, #6,028 in Biotechnology and Pharmaceuticals.
- Monthly visits2.6K
▼ 20.4% vs previous month
- Unique visitors1.5K
per month
- Global rank#5,347,385
among all websites
- Category rank#6,028
Health · Biotechnology and Pharmaceuticals
- Bounce rate32%
- Pages per visit1.5
- Average visit17 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with Genexine. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
hanall.co.kr | hanall.co.kr | 100% | – | ||
| celltrion.com | 96% | 179.3K | #287,455 | View details | |
ncc.re.kr | ncc.re.kr | 58% | #240,790 | – | |
| medicopharma.co.kr | 57% | #596,014 | View details | ||
dailymedi.com | dailymedi.com | 57% | #145,758 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genexine
Complete news archive for Genexine
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genexine
Genexine was founded in 2002 and raised its 1st funding round 10 years after it was founded.
Genexine is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Neil Warma is the CEO of Genexine, as recorded in our data.
Genexine has 89 employees.
Annual revenue of Genexine is $3.16M as on Dec 31, 2025.
Genexine was founded in 2002 in Seongnam-si, South Korea. Focus is placed on developing immunotherapeutics targeting orphan diseases, cancers, and autoimmune disorders within the biotechnology sector. Drug candidates for growth hormone deficiencies, cervical cancers, and anemias have been advanced. The technology platform relies on Fc fusion proteins and DNA vaccines for these operations.
Yes, Genexine is publicly traded on KRX under the ticker symbol 095700.
Genexine has made 1 acquisition, including Argos Therapeutics.
Genexine has 1 investor. Key investors include Handok.